

Strong Demand in Share Placement to Raise \$3.5 million to Progress

ColoSTAT® Multiplex Colorectal Cancer Test

Highlights:

- ✓ Rhythm Biosciences to raise \$3.5 million at an issue price of \$0.10 per share, plus two (2) New Options for every three (3) New Shares subscribed for under the Offer (Options are subject to shareholder approval);
- ✓ Placement demand was strong and supported by several new institutional, professional and sophisticated investors; and
- ✓ Funds will be used primarily to advance and commercialise the ColoSTAT® Multiplex diagnostic Colorectal Cancer test.

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: RHY) (**Rhythm** or the **Company**), is pleased to advise that it has received commitments for a capital raising, comprising a Placement (**Placement**), to raise \$3.5 million (before costs) at a price of \$0.10 per new fully paid ordinary share (**Placement Share**).

The Placement will raise approximately \$3.5 million before costs via a single tranche issue of approximately 35,000,000 new fully paid Placement Shares at \$0.10 per Placement Share (**Offer Price**), together with 2 (two) listed options (with an exercise price of \$0.20, expiring on 31 March 2026) (**Placement Options**) for every 3 (three) Placement Shares issued, and subject to RHY shareholder approval, as below. The Placement Options will be listed on the ASX and be of the same class as the existing ASX-listed options (ASX: RHYO).

The Offer Price for the Placement represents a:

- 13.0% discount to the last closing price of \$0.115 on 14 November 2024 (being the last day of trading of RHY shares prior to this announcement);
- 19.5% discount to the 5-day VWAP ("**Volume Weighted Average Price**") of \$0.124 per share; and
- 11.4% discount to the 15-day VWAP of \$0.113 per share.

The funds raised from the Placement are intended to be applied to:

- complete the new ColoSTAT® Multiplex test kit development;
- complete clinical validation of the new ColoSTAT® Multiplex test kit;
- continue to progress R&D pipeline development activities into other cancers, both organically and via inorganic means; and
- for general working capital purposes.

Directors

Rhythm's Managing Director, Dr David Atkins, commented: *"We are delighted by the strong interest from a majority of new shareholders and warmly welcome both the institutional investors and the many experienced individuals who have joined the Company. The demand is a clear signal of renewed confidence in our ColoSTAT® product and our upcoming commercial validation strategy. We remain committed to collaborating with industry experts and advancing talks with potential partners to bring our colorectal test to market, ultimately fulfilling our mission of improving diagnostic outcomes for bowel cancer. We extend our gratitude to our current shareholders for their continued support and are excited to welcome new investors to our shareholder base."*

The Placement Shares will be fully paid ordinary shares, will rank equally with the Company's existing issued Shares and the Company will make an application to the ASX for the official quotation of the new Placement Shares. Following shareholder approval, the Company also intends to make an application to the ASX for the official quotation of the Placement Options under the Placement as addition securities under the same class of current listed option securities (ASX: RHYO).

The table below sets out, for illustrative purposes only, the existing Share capital structure (before the Placement) together with the impact of the issue of the Placement Shares. It assumes that no options are exercised.

Shares	Number
Existing Shares as at date of the Placement (includes 6m unlisted loan-funded Shares)	254,596,750
Maximum number of Placement Shares issued under the Placement (approximately)	35,000,000
Total issued Shares following completion of the Placement (assuming full allotment under the Placement)	289,596,750

PAC Partners Securities Pty Ltd and CPS Capital Group Pty Ltd acted as Joint Lead Managers to the Placement.

Further information pertaining to the Placement is available in the Prospectus to be lodged with the ASX on 19 November 2024.

The following is an indicative timetable for the Placement:

Indicative Placement Offer Timetable¹ Event	Date
Placement Offer announcement and Company resumes trading	19 November 2024
Release of Prospectus on ASX	19 November 2024
Allotment and issue of New Shares under Placement Issue	27 November 2024
Expected normal trading of New Shares under Placement Offer	28 November 2024
General Meeting to approve attaching Options	Late January – early February 2025

1. Dates are indicative and subject to change.

- ENDS -

Authorised for release by the Board.

About Rhythm Biosciences

Rhythm Biosciences Limited (Rhythm, RHY or the Company) engages in developing and commercialising innovative and non-invasive medical diagnostics technology in Australia and internationally. It develops ColoSTAT®, a blood test for the early detection of colorectal cancer (CRC). CRC is a progressive disease associated with increased risk of mortality and substantial healthcare and societal cost. With 1.93m new cases and ~940,000 deaths annually, CRC is the second largest cause of cancer death. Developed by a world-class team of scientists and clinicians, ColoSTAT® leverages a unique panel of biomarkers to detect early-stage colorectal cancer with high accuracy. While the Company's focus is on the early detection of CRC, the platform also has the future capability to detect early-stage breast, lung, gastric, cervical and pancreatic cancers.

The Company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit rhythmbio.com and follow the Company on LinkedIn and X.

For further information contact us via investor@rhythmbio.com:

Dr. David Atkins Chief Executive Officer	Mr. Guy Carisbrooke Financial Controller
--	--